Plus   Neg

Stealth BioTherapeutics Prices IPO At $12/ADS, The Low End Of Expected Range

Stealth BioTherapeutics (MITO) announced the pricing of initial public offering of 6.5 million American Depositary Shares or ADSs at $12.00 per ADS, the lower end of the expected range of between $12 and $14 per ADS. The offering is expected to close on February 20, 2019.

Stealth stated that its ADSs are expected to begin trading on February 15, 2019 under the ticker symbol "MITO."

The clinical-stage biotechnology company focused on novel therapies for diseases involving mitochondrial dysfunction expects total offering gross proceeds, before expenses, to be $78.0 million.

Stealth also granted the underwriters a 30-day option to buy additional 975,000 ADSs on the same terms and conditions.

Jefferies LLC, Evercore Group L.L.C. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Nomura Securities International, Inc. is acting as the lead manager for the offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Worldpay, Inc. were gaining around 12 percent in London after the eCommerce and payments technology company announced its agreement to be merged with FIS, a U.S. financial services technology company. The combination of stock and cash values Worldpay at an enterprise value of approximately $43 billion, including the assumption of Worldpay debt. Germany's two biggest lenders, Deutsche Bank (DB) and Commerzbank (CRZBY.PK) Sunday confirmed they are in discussions to potential merge. France's National Council of Clerks or NCC, the representative entity of commercial courts' clerks, has successfully deployed an IBM blockchain network, to streamline the management of commercial and corporate registry. The move is expected to improve management of legal transactions related to the companies, and bring better transparency and efficiency.
Follow RTT